Clinical Trials Logo

Clinical Trial Summary

In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins. Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

Clinical Trial Description

Properties - Anti-oxidant, vascular protector - Inhibition of platelet aggregation, vasorelaxant , arterial relaxant - Anti-hypertensive , especially by certain derivatives (quercetin-3-glucuronic acid) - Nephroprotective in rats, protects against the nephrotoxicity of gentamicin - Anticancer , with immunostimulatory activity and inducer of apoptosis, with activity on the shock proteins HSP (heat shock proteins) hsp27 and hsp70 - Antitumor activity against prostate cancer and certain breast cancer cells - Prevention of cardiac toxicity from doxorubicin, with resveratrol - Protection against gastric inflammation associated with Helicobacter pylori infection by activity on MAPK, BCL-2, BAX. - Increases the antitoxic activity of the liver - Pancreatic lipase inhibitor, potential action in weight gain - Anti-inflammatory - Anti-allergic, inhibition of mast cell degranulation, with a preventive effect, reduction of inflammation linked to eosinophils (such as isoquercitrin regulates the Th1 / Th2 balance - Antiviral (dose-dependent reduction of infectivity, decreases intracellular replication) - Inhibition of rhinovirus replication - Influenza prophylaxis by quercetin or its derivatives (quercetin-3-O-α-L-rhamnopyranoside), opposes the pro-oxidant effects induced by the influenza virus, antioxidant therapy could be used to prevent serious complications associated with influenza - In vitro inhibition of the penetration of the Ebola virus by quercetin-3-O-glucoside - Antiviral activity against Zika virus, hepatitis B virus, hepatitis C, Epstein-Barr virus EBV and antitumor against human gastric carcinoma ;

Study Design

Related Conditions & MeSH terms

  • SARS (Severe Acute Respiratory Syndrome)
  • Severe Acute Respiratory Syndrome

NCT number NCT04853199
Study type Interventional
Source Hôpital Universitaire Sahloul
Contact Boukef Riadh, professor
Phone 98676745
Email [email protected]
Status Not yet recruiting
Phase Early Phase 1
Start date April 25, 2021
Completion date August 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04784481 - Ivermectin Reproposing for Mild Stage COVID-19 Outpatients Phase 1/Phase 2
Recruiting NCT04584658 - Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Active, not recruiting NCT04546581 - Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Completed NCT04701710 - Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan Phase 1/Phase 2
Not yet recruiting NCT04590274 - Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Phase 1
Recruiting NCT04644159 - Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]
Enrolling by invitation NCT04540185 - A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 Phase 3
Recruiting NCT04382391 - Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms N/A
Recruiting NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Active, not recruiting NCT04390412 - Low Dose Radiotherapy in COVID-19 Pneumonia Phase 1/Phase 2
Recruiting NCT04559113 - Methylprednisolone in COVID-19 Patients (Methyl19LGH) N/A
Recruiting NCT04560257 - High Flow Nasal Cannula HFNC In Covid-19 Patients N/A
Completed NCT04328961 - Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) Phase 2/Phase 3
Completed NCT04480580 - Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery
Withdrawn NCT04290871 - Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. Phase 2